HUNTSVILLE — Biospecimen and biomarker specialists, Discovery Life Sciences said its Discovery Genomics lab is the first commercial service laboratory in the world to receive two of the new NovaSeq X Plus Sequencing Systems from Illumina.
Discovery Genomics will expand its platform to five systems by the end of the year, positioning itself as the commercial laboratory with the world’s largest NovaSeq X Plus commercial fleet.
The NovaSeq X Plus is a game-changer in the field of genomics, Discovery Genomics said in a news release. Its ultra-high-density flow cells and ultra-high-resolution optics enable output of up to 26 billion single reads per flow cell.
The system can simultaneously perform up to four applications per flow cell, with integrated secondary analysis capabilities, making it a uniquely powerful and versatile tool for genomics research.
“With the expansion of our fleet to five systems, we are uniquely positioned to provide the highest capacity to generate genomic data more cost effectively, furthering our mission to enable our clients’ success by delivering world-class genomic services with speed, scale, and quality,” said Dr. Tom Halsey, executive vice president of Discovery Genomics
Discovery Genomics said the X Plus will help provide the highest quality results at substantially reduced costs and timelines.
“Cross-validation of our existing WGS, WES, RNA-Seq libraries for both standard and low input workflows on the newly installed Illumina NovaSeq X Plus instruments has already begun,” said Dr. Nripesh Prasad, vice president of scientific and technical development for Discovery Genomics. “This cross-validation data will help us quickly bridge the NovaSeq 6000 and X-Plus chemistries so customers can confidently utilize the new technology for their high-throughput projects at unprecedented speed and scale while reducing their overall project costs.”
Discovery’s CLIA-certified, CAP-accredited, and GCLP-compliant genomics laboratory offers a wide range of scalable next-generation sequencing services, including RNA, whole exome, whole genome, targeted, single cell, and epigenetic sequencing.
Its proprietary comprehensive genomic profiling workflow enables interrogation of most difficult sample types, such as formalin-fixed paraffin-embedded and core needle biopsies samples.
Discovery Life Sciences will be moving to a 100,000 square-foot world headquarters this summer. Here it will house one of the largest installments of the leading edge multi-omic biomarker technologies, including the Illumina NovaSeq X Plus Systems, under one roof.
The facility will host genomics, proteomics, molecular pathology, and flow cytometry laboratories. A fully integrated LIMS system will track the chain of custody of a research or clinical trial sample from receipt through multiple technologies, producing comprehensive and actionable data in the shortest possible time.
Don’t miss out! Subscribe to our email newsletter to have all our smart stories delivered to your inbox.
